The Hidden Achilles Heel of Cancer
The Double Agent Problem
Cancer has a traitor hiding in plain sight. Macrophages — the immune cells meant to hunt and destroy foreign invaders — get hijacked by tumors, where they prepare the groundwork for growth, blood vessel formation, and metastasis.
The trouble is, these corrupted cells, called tumor-associated macrophages (TAMs), look nearly identical to their healthy counterparts scattered throughout the body. Any therapy targeting them risks significant collateral damage to normal tissue.
The discovery of RXRB represents the first known surface receptor exclusive to TAMs — a potential molecular address for precision cancer treatment.
A Receptor Unlike Any Other
Researchers at the University of Minnesota's College of Pharmacy, working alongside collaborators at Sanford Burnham Prebys Medical Discovery Institute, may have found a way to distinguish friend from foe. Their team has identified a surface receptor found exclusively on TAMs — never on macrophages in normal organs.
That marker, a protein called RXRB, could become the delivery address for drug systems that seek out and treat tumors without poisoning healthy tissue.
Step 1
The team used phage display — inserting random DNA fragments into bacteria-infecting viruses to generate vast libraries of viral particles, each decorated with a different peptide on its surface.
Step 2
Exposing these libraries to macrophages narrowed the field to a peptide that stuck specifically to TAMs — a snippet the team named CRV.
Step 3
CRV was injected into mice carrying various tumors, where it navigated from the bloodstream into solid tumor tissue and latched onto macrophages while leaving healthy organs untouched.
Step 4
Experiments confirmed CRV binds specifically to the RXRB receptor — and critically, macrophages from normal organs showed no trace of RXRB.
From Discovery to Drug Delivery
To test whether CRV could carry therapeutic cargo, the researchers attached it to nanoparticles and injected them into mice with mammary tumors. The modified particles accumulated in tumors far more efficiently than untethered nanoparticles.
This validates that CRV can ferry chemotherapy or other drugs directly to the cells that tumors depend on — without the harmful side effects of conventional treatment.
The work appears in the Journal of Controlled Release.
What Comes Next
The implications extend far beyond a single drug delivery vehicle. If the findings hold up in further testing, RXRB could open a menu of options: from precision chemotherapy delivery to molecules that reprogram TAMs from tumor enablers into tumor fighters.
The receptor now has both a name and a function — a new address on a cell that cancer biologists have long wanted to exploit.
Based on: Identification of a TAM-specific peptide and its receptor; University of Minnesota College of Pharmacy and Sanford Burnham Prebys Medical Discovery Institute; Journal of Controlled Release.